These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
166 related articles for article (PubMed ID: 38563846)
1. Prognostic model based on B cell marker genes for NSCLC patients under neoadjuvant immunotherapy by integrated analysis of single-cell and bulk RNA-sequencing data. Liu Y; Bie F; Bai G; Huai Q; Li Y; Chen X; Zhou B; Gao S Clin Transl Oncol; 2024 Aug; 26(8):2025-2036. PubMed ID: 38563846 [TBL] [Abstract][Full Text] [Related]
2. Integrated analysis of single-cell and bulk RNA-sequencing identifies a signature based on B cell marker genes to predict prognosis and immunotherapy response in lung adenocarcinoma. Song P; Li W; Wu X; Qian Z; Ying J; Gao S; He J Cancer Immunol Immunother; 2022 Oct; 71(10):2341-2354. PubMed ID: 35152302 [TBL] [Abstract][Full Text] [Related]
3. Machine-learning and combined analysis of single-cell and bulk-RNA sequencing identified a DC gene signature to predict prognosis and immunotherapy response for patients with lung adenocarcinoma. Zhang L; Guan M; Zhang X; Yu F; Lai F J Cancer Res Clin Oncol; 2023 Nov; 149(15):13553-13574. PubMed ID: 37507593 [TBL] [Abstract][Full Text] [Related]
4. Integrated analysis of single-cell and bulk RNA-sequencing identifies a signature based on T-cell marker genes to predict prognosis and therapeutic response in lung squamous cell carcinoma. Shi X; Dong A; Jia X; Zheng G; Wang N; Wang Y; Yang C; Lu J; Yang Y Front Immunol; 2022; 13():992990. PubMed ID: 36311764 [TBL] [Abstract][Full Text] [Related]
5. Insights into the heterogeneity of the tumor microenvironment in lung adenocarcinoma and squamous carcinoma through single-cell transcriptomic analysis: Implications for distinct immunotherapy outcomes. Fang X; Li D; Wan S; Hu J; Zhang P; Jie D; Chen L; Jiang G; Song N J Gene Med; 2024 Jun; 26(6):e3694. PubMed ID: 38847309 [TBL] [Abstract][Full Text] [Related]
6. Construction of a B cell-related gene pairs signature for predicting prognosis and immunotherapeutic response in non-small cell lung cancer. Li X; Wang R; Wang S; Wang L; Yu J Front Immunol; 2022; 13():989968. PubMed ID: 36389757 [TBL] [Abstract][Full Text] [Related]
7. T cell-related prognostic risk model and tumor immune environment modulation in lung adenocarcinoma based on single-cell and bulk RNA sequencing. Zhang J; Liu X; Huang Z; Wu C; Zhang F; Han A; Stalin A; Lu S; Guo S; Huang J; Liu P; Shi R; Zhai Y; Chen M; Zhou W; Bai M; Wu J Comput Biol Med; 2023 Jan; 152():106460. PubMed ID: 36565482 [TBL] [Abstract][Full Text] [Related]
8. Identification and Validation of a Tumor Microenvironment-Related Gene Signature for Prognostic Prediction in Advanced-Stage Non-Small-Cell Lung Cancer. Zhang X; Shi X; Zhao H; Jia X; Yang Y Biomed Res Int; 2021; 2021():8864436. PubMed ID: 33860055 [TBL] [Abstract][Full Text] [Related]
9. Prognostic characterization of immune molecular subtypes in non-small cell lung cancer to immunotherapy. Li C; Pan J; Luo J; Chen X BMC Pulm Med; 2021 Nov; 21(1):389. PubMed ID: 34844602 [TBL] [Abstract][Full Text] [Related]
10. Mast cell marker gene signature: prognosis and immunotherapy response prediction in lung adenocarcinoma through integrated scRNA-seq and bulk RNA-seq. Zhang P; Liu J; Pei S; Wu D; Xie J; Liu J; Li J Front Immunol; 2023; 14():1189520. PubMed ID: 37256127 [TBL] [Abstract][Full Text] [Related]
11. Integrative analyses of bulk and single-cell RNA-seq identified cancer-associated fibroblasts-related signature as a prognostic factor for immunotherapy in NSCLC. Wang S; Fan G; Li L; He Y; Lou N; Xie T; Dai L; Gao R; Yang M; Shi Y; Han X Cancer Immunol Immunother; 2023 Jul; 72(7):2423-2442. PubMed ID: 37010552 [TBL] [Abstract][Full Text] [Related]
12. Choline metabolism reprogramming mediates an immunosuppressive microenvironment in non-small cell lung cancer (NSCLC) by promoting tumor-associated macrophage functional polarization and endothelial cell proliferation. Xiao B; Li G; Gulizeba H; Liu H; Sima X; Zhou T; Huang Y J Transl Med; 2024 May; 22(1):442. PubMed ID: 38730286 [TBL] [Abstract][Full Text] [Related]
13. Based on scRNA-seq and bulk RNA-seq to establish tumor immune microenvironment-associated signature of skin melanoma and predict immunotherapy response. Li S; Zhao J; Wang G; Yao Q; Leng Z; Liu Q; Jiang J; Wang W Arch Dermatol Res; 2024 May; 316(6):262. PubMed ID: 38795156 [TBL] [Abstract][Full Text] [Related]
14. Single-cell RNA sequencing reveals microenvironmental infiltration in non-small cell lung cancer with different responses to immunotherapy. Hu X; Wu Y; Wang L; Yang F; Ye L; Chen X; Song X; Wei P J Gene Med; 2024 Sep; 26(9):e3736. PubMed ID: 39228151 [TBL] [Abstract][Full Text] [Related]
15. Integrated analysis of single-cell and bulk RNA-sequencing identifies a signature based on T-cell marker genes to predict prognosis and immunotherapy response in bladder cancer. Shi X; Dong A; Yang Y; Zheng G; Wang N; Yang C; Wang Y; Lu J; Jia X J Cancer Res Clin Oncol; 2023 Sep; 149(12):9733-9746. PubMed ID: 37244876 [TBL] [Abstract][Full Text] [Related]
16. RNA modification writer expression profiles predict clinical outcomes and guide neoadjuvant immunotherapy in non-small cell lung cancer. Zhou B; Bie F; Zang R; Zhang M; Song P; Liu L; Peng Y; Bai G; Zhao J; Gao S EBioMedicine; 2022 Oct; 84():104268. PubMed ID: 36116215 [TBL] [Abstract][Full Text] [Related]
17. Identification and Validation of a Novel Signature Based on NK Cell Marker Genes to Predict Prognosis and Immunotherapy Response in Lung Adenocarcinoma by Integrated Analysis of Single-Cell and Bulk RNA-Sequencing. Song P; Li W; Guo L; Ying J; Gao S; He J Front Immunol; 2022; 13():850745. PubMed ID: 35757748 [TBL] [Abstract][Full Text] [Related]
18. Identification of immune activation-related gene signature for predicting prognosis and immunotherapy efficacy in lung adenocarcinoma. Zeng W; Wang J; Yang J; Chen Z; Cui Y; Li Q; Luo G; Ding H; Ju S; Li B; Chen J; Xie Y; Tong X; Liu M; Zhao J Front Immunol; 2023; 14():1217590. PubMed ID: 37492563 [TBL] [Abstract][Full Text] [Related]
19. Dynamics of peripheral blood inflammatory index predict tumor pathological response and survival among patients with locally advanced non-small cell lung cancer who underwent neoadjuvant immunochemotherapy: a multi-cohort retrospective study. Zhai W; Zhang C; Duan F; Xie J; Dai S; Lin Y; Yan Q; Rao B; Li L; Zhou Y; Zhao Z; Long H; Wang J Front Immunol; 2024; 15():1422717. PubMed ID: 39108262 [TBL] [Abstract][Full Text] [Related]
20. Development and Validation of an Individualized Immune Prognostic Signature in Early-Stage Nonsquamous Non-Small Cell Lung Cancer. Li B; Cui Y; Diehn M; Li R JAMA Oncol; 2017 Nov; 3(11):1529-1537. PubMed ID: 28687838 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]